
CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original […]
VANCOUVER, Washington, March 27, 2020 — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]
Dr. Richard Pestell, who leads CytoDyn’s cancer, NASH and GvHD programs, recently named to The Order of Australia, established by Queen Elizabeth II VANCOUVER, Washington, June 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.